Page last updated: 2024-08-23

bezafibrate and Liver Cirrhosis, Biliary

bezafibrate has been researched along with Liver Cirrhosis, Biliary in 69 studies

Research

Studies (69)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	13 (18.84)	29.6817
2010's	36 (52.17)	24.3611
2020's	20 (28.99)	2.80

Authors

Authors	Studies
Avagnina, A; Barreyro, FJ; Carballo, P; Daruich, J; González Ballerga, E; Paes de Lima, A; Sorda, JA	1
Barreyro, FJ; Daruich, J; González Ballerga, E; Sorda, JA	1
Banales, JM; Rodrigues, PM	1
Khakoo, NS; Levy, C; Reynolds, JM; Sultan, S	1
Bowlus, CL; Liu, CH	1
Düll, MM; Kremer, AE	1
Barba Bernal, R; Bonder, A; Ferrigno, B; Gerger, H; Goyes, D; Medina-Morales, E; Patwardhan, V; Trivedi, HD	1
Amano, K; Hidaka, A; Ishida, J; Ishikawa, T; Mizuno, Y; Nakano, M; Oikawa, T; Saeki, C; Saruta, M; Takakura, K; Takano, K; Torisu, Y; Tsubota, A; Zeniya, M	1
Kowdley, KV; Shah, RA	1
Chazouillères, O; Corpechot, C; Rousseau, A	2
Harms, MH; van Buuren, HR; van der Meer, AJ	1
de Veer, RC; Laschtowitz, A; Schramm, C; Van der Meer, AJ	1
Abe, M; Aiso, M; Arakawa, M; Arizumi, T; Asaoka, Y; Fujii, H; Hashimoto, N; Honda, A; Inao, M; Itakura, J; Joshita, S; Kakisaka, K; Kaneko, A; Kang, JH; Kawada, N; Kawata, K; Kikuchi, K; Komori, A; Masaki, T; Matsumoto, K; Miura, R; Mochida, S; Namisaki, T; Ninomiya, M; Nomura, T; Ohira, H; Sato, K; Takahashi, A; Takamura, M; Takikawa, H; Takikawa, Y; Tamura, Y; Tanaka, A; Umemura, T; Yagi, M; Yoshiji, H	1
Beuers, U; Bolier, R; de Vree, M; de Vries, E; Drenth, J; Goet, J; Helder, J; Mostafavi, N; Oude Elferink, R; Parés, A; Ponsioen, C; van Buuren, H; van der Heide, F; van Erpecum, K; van Nieuwkerk, K; Verbeek, J	1
Korf, H; Nevens, F; Smets, L; van der Merwe, S; Verbeek, J	1
Carrion, AF; Levy, C; Lindor, KD	1
Carrat, F; Chazouillères, O; Corpechot, C; Hansen, BE; Hirohara, J; Matsumoto, K; Nakano, T; Takikawa, H; Tanaka, A	1
Hasegawa, S; Honda, Y; Hosono, K; Kurita, Y; Nakajima, A; Nogami, A; Yoneda, M	1
Albillos, A; Álvarez-Navascués, C; Andrade, RJ; Arencibia, A; Berenguer, M; Casado, M; Chahri, N; De la Cruz, G; Diago, M; Estevez, P; Fábrega, E; Fernandez-Bonilla, E; Fernández-Rodriguez, CM; Ferre-Aracil, C; Gallego-Moya, A; Gómez-Camarero, J; Gómez-Domínguez, E; González-Santiago, JM; Hernández-Guerra, M; Hijona, L; Horta, D; Molina, E; Morillas, RM; Parés, A; Pérez-Medrano, IM; Reig, A; Romero-Gomez, M; Sala, M; Suárez, F; Vargas, V; Vergara, M	1
Miao, H; Pan, J; Shen, N; Xing, L; Yu, X; Zhang, H	1
Beuers, U; Bolier, R; de Vries, ES; Elferink, RPO; Helder, J; Kemper, EM; Parés, A; Zwinderman, K	1
Parés, A; Reig, A; Sesé, P	1
Strassburg, CP	1
Levy, C; Lindor, KD	1
Abergel, A; Admane, FH; Boursier, J; Bronowicki, JP; Chazouillères, O; Chollet-Martin, S; Corpechot, C; de Chaisemartin, L; de Ledinghen, V; Debette-Gratien, M; Gaouar, F; Goria, O; Habersetzer, F; Heurgue-Berlot, A; Humbert, L; Larrey, D; Le Gruyer, A; Lefèvre, G; Lemoinne, S; Mathurin, P; Minello, A; Nguyen-Khac, E; Nkontchou, G; Ollivier-Hourmand, I; Potier, P; Poupon, R; Rainteau, D; Rousseau, A; Roux, O; Silvain, C; Simon, T; Zarski, JP; Zoulim, F	1
Hegade, VS; Jones, DE	1
Chazouillères, O; Chollet-Martin, S; Corpechot, C; De Chaisemartin, L; Humbert, L; Kremer, AE; Le Cleac'h, A; Lemoinne, S; Poupon, R; Rainteau, D; Rousseau, A; Wolf, K	1
Bahar, R; Bowlus, CL; Liu, CH; Wong, KA	1
Hirschfield, GM; Webb, GJ	1
Korula, J	1
Klose, G; Nitschmann, S	1
Chazouillères, O; Corpechot, C; Lemoinne, S; Rousseau, A	1
Pratt, DS	1
Feng, BL; Shen, W; Yu, HH	1
Chang, Y; Cho, EJ; Chung, SW; Kim, MA; Kim, SW; Kim, YJ; Lee, HY; Lee, JH; Lee, YB; Leem, G; Park, JY; Yoon, JH; Yoon, JS; Yu, SJ	1
Cao, H; Hu, M; Su, T; Wang, Y; Wang, Z; Zhang, B; Zhang, P	1
Bruguera, M; Lens, S; Leoz, M; Nazal, L; Parés, A	1
Dohmen, K; Haruno, M; Tanaka, H	1
Ando, M; Harada, K; Hirohata, M; Miyake, Y; Moriya, A; Nakanuma, Y; Takemoto, R; Yamamoto, K	1
Hirohara, J; Nakanuma, Y; Takikawa, H; Tanaka, A; Tsubouchi, H	1
Hashizume, H; Horiguchi, N; Hosonuma, K; Kakizaki, S; Kusano, M; Sato, K; Yamada, M; Yamazaki, Y; Yanagisawa, M	1
Braddock, M; Chen, YP; Huang, GQ; Huang, S; Lin, YQ; Shi, KQ; Wang, JT; Wang, LR; Wu, YM; Zheng, MH; Zhou, MT; Zhou, ZR; Zhu, GQ	1
Castellaneta, NM; Di Leo, A; Facciorusso, A; Licinio, R	1
Hosonuma, K; Kusano, M; Sato, K; Yamada, M	1
Abudumijiti, H; Chen, K; Chen, R; Guo, C; Li, J; Li, S; Liu, T; Lu, J; Lu, W; Wang, F; Wang, J; Xia, Y; Yin, Q; Zhang, R; Zheng, Y; Zhou, Y	1
Czul, F; Levy, C	1
Himoto, T; Iwama, H; Masaki, T; Miyoshi, H; Morishita, A; Nomura, T; Sakamoto, T; Tani, J; Yoneyama, H	1
Bassendine, MF; Jones, DE; Newton, J; Walker, LJ	1
Enjoji, M; Fujino, T; Harada, N; Higuchi, N; Kato, M; Kohjima, M; Kotoh, K; Machida, K; Maehara, Y; Matsunaga, K; Nakamuta, M; Nakashima, M; Nishinakagawa, T; Taketomi, A; Yada, M; Yada, R; Yasutake, K; Yoshimoto, T	1
Fujioka, S; Ikeda, F; Itoshima, T; Iwasaki, Y; Kobashi, H; Miyake, Y; Osawa, T; Takaki, A; Takaki, T; Takeuchi, Y; Yamamoto, K; Yasunaka, T	1
Abe, K; Kanno, Y; Katsushima, F; Monoe, K; Ohira, H; Saito, H; Takahashi, A; Yokokawa, J	1
Chapman, RW; Halliday, JS	1
Bjelakovic, G; Gluud, C; Krstic, MN; Poropat, G; Rudic, JS	1
Hirayama, T; Honda, A; Ikegami, T; Imawari, M; Iwamoto, J; Matsuzaki, Y; Miyazaki, T; Nakamuta, M; Saito, Y; Takikawa, H	1
Boyer, JL; Ghonem, NS	1
Tanaka, A	1
Imazeki, F; Kanda, T; Saisho, H; Yokosuka, O	1
Zeniya, M	1
Abe, M; Akbar, SM; Furukawa, S; Horiike, N; Nakanishi, S; Onji, M	1
Enjoji, M; Kotoh, K; Nakamuta, M; Shimohashi, N; Tanabe, Y	1
Lengyel, G; Tulassay, Z	1
Ohmoto, K; Yamamoto, S; Yoshioka, N	1
Kimura, T; Kita, R; Kokuryu, H; Osaki, Y; Takamatsu, S; Tomono, N	1
Deguchi, A; Kurokohchi, K; Masaki, T; Nakai, S; Nishioka, M	1
Kurihara, T; Maeda, A; Niimi, A; Shigemoto, M; Yamashita, K	1
Mitsui, Y; Ohmoto, K; Yamamoto, S	1
Hashimoto, E; Kurihara, T; Maeda, A; Shigemoto, M; Yamashita, K	1
Furukawa, R; Ishibashi, H; Kato, H; Morita, S; Takahara, O; Yano, K	1

Reviews

18 review(s) available for bezafibrate and Liver Cirrhosis, Biliary

Article	Year
Efficacy and Safety of Bezafibrate Alone or in Combination with Ursodeoxycholic Acid in Primary Biliary Cholangitis: Systematic Review and Meta-Analysis. Digestive diseases and sciences, 2023, Volume: 68, Issue:4 Topics: Bezafibrate; Cholagogues and Choleretics; Drug Therapy, Combination; Humans; Liver Cirrhosis, Biliary; Quality of Life; Ursodeoxycholic Acid	2023
Treatment of Primary Biliary Cholangitis: First-Line and Second-Line Therapies. Clinics in liver disease, 2022, Volume: 26, Issue:4 Topics: Autoimmune Diseases; Bezafibrate; Cholagogues and Choleretics; Cholangitis; Humans; Liver Cirrhosis, Biliary; Ursodeoxycholic Acid	2022
Evaluation and Management of Pruritus in Primary Biliary Cholangitis. Clinics in liver disease, 2022, Volume: 26, Issue:4 Topics: Albumins; Bezafibrate; Humans; Liver Cirrhosis, Biliary; Narcotic Antagonists; Pruritus; Receptors, Opioid; Receptors, Serotonin; Rifampin; Selective Serotonin Reuptake Inhibitors	2022
Pharmacological Therapy of Pruritus in Primary Biliary Cholangitis: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. Journal of clinical gastroenterology, 2023, 02-01, Volume: 57, Issue:2 Topics: Antipruritics; Bezafibrate; Humans; Liver Cirrhosis, Biliary; Pruritus; Randomized Controlled Trials as Topic; Treatment Outcome	2023
Current and potential treatments for primary biliary cholangitis. The lancet. Gastroenterology & hepatology, 2020, Volume: 5, Issue:3 Topics: Benzothiazoles; Bezafibrate; Bile Acids and Salts; Budesonide; Case-Control Studies; Chenodeoxycholic Acid; Cholagogues and Choleretics; Clinical Trials as Topic; Cyclosporine; Disease Progression; Glucocorticoids; Homeostasis; Humans; Immunologic Factors; Immunosuppressive Agents; Isoxazoles; Liver Cirrhosis, Biliary; Liver Transplantation; Peroxisome Proliferator-Activated Receptors; Receptors, Cytoplasmic and Nuclear; Rituximab; Treatment Outcome; United States; United States Food and Drug Administration; Ursodeoxycholic Acid	2020
Diagnosis and treatment of primary biliary cholangitis. United European gastroenterology journal, 2020, Volume: 8, Issue:6 Topics: Autoantigens; Autoimmune Diseases; Bezafibrate; Biomarkers; Biopsy; Chenodeoxycholic Acid; Cholagogues and Choleretics; Disease Progression; Drug Therapy, Combination; Elasticity Imaging Techniques; End Stage Liver Disease; Fatigue; Female; Humans; Immunoglobulin M; Liver; Liver Cirrhosis, Biliary; Liver Function Tests; Liver Transplantation; Middle Aged; Off-Label Use; Prognosis; Pruritus; Quality of Life; Severity of Illness Index; Sjogren's Syndrome; Survival Rate; Treatment Outcome; Ursodeoxycholic Acid	2020
Safety of fibrates in cholestatic liver diseases. Liver international : official journal of the International Association for the Study of the Liver, 2021, Volume: 41, Issue:6 Topics: Bezafibrate; Cholagogues and Choleretics; Fibric Acids; Humans; Liver Cirrhosis, Biliary; Ursodeoxycholic Acid	2021
Cholestatic Liver Disease: Current Treatment Strategies and New Therapeutic Agents. Drugs, 2021, Volume: 81, Issue:10 Topics: Anti-Bacterial Agents; Bezafibrate; Cholagogues and Choleretics; Cholangitis, Sclerosing; Fibroblast Growth Factors; Glucocorticoids; Hepatitis, Autoimmune; Humans; Immunosuppressive Agents; Liver Cirrhosis, Biliary; Peroxisome Proliferator-Activated Receptors; Probiotics; Receptors, Cytoplasmic and Nuclear; Tumor Necrosis Factor-alpha	2021
Fibrates for the treatment of pruritus in primary biliary cholangitis: a systematic review and meta-analysis. Annals of palliative medicine, 2021, Volume: 10, Issue:7 Topics: Bezafibrate; Fibric Acids; Humans; Liver Cirrhosis, Biliary; Pruritus; Ursodeoxycholic Acid	2021
[Modern treatment of primary biliary cholangitis]. Der Internist, 2018, Volume: 59, Issue:1 Topics: Bezafibrate; Budesonide; Chenodeoxycholic Acid; Cohort Studies; Female; Fenofibrate; Humans; Liver Cirrhosis, Biliary; Liver Transplantation; Male; Multicenter Studies as Topic; PPAR alpha; Pregnancy; Prognosis; Quality of Life; Receptors, Cytoplasmic and Nuclear; Risk Assessment; Treatment Outcome; Ursodeoxycholic Acid	2018
Current Treatment Options for Primary Biliary Cholangitis. Clinics in liver disease, 2018, Volume: 22, Issue:3 Topics: Alkaline Phosphatase; Bezafibrate; Chenodeoxycholic Acid; Cholagogues and Choleretics; Comorbidity; Drug Therapy, Combination; Fenofibrate; Fibroblast Growth Factors; Humans; Hypolipidemic Agents; Immunosuppressive Agents; Liver Cirrhosis, Biliary; Malnutrition; Osteoporosis; Peroxisome Proliferator-Activated Receptors; Receptors, Cytoplasmic and Nuclear; Ursodeoxycholic Acid	2018
Work in Progress: Drugs in Development. Clinics in liver disease, 2018, Volume: 22, Issue:3 Topics: Abatacept; Acetates; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Bezafibrate; CD40 Antigens; CD40 Ligand; Chalcones; Chemokine CX3CL1; Chenodeoxycholic Acid; Cholic Acids; Drug Development; Fenofibrate; Fibroblast Growth Factors; Humans; Hypolipidemic Agents; Immunosuppressive Agents; Janus Kinase Inhibitors; Liver Cirrhosis, Biliary; Methylamines; Peroxisome Proliferator-Activated Receptors; PPAR alpha; PPAR delta; PPAR gamma; Propionates; Pruritus; Receptors, Cytoplasmic and Nuclear; Receptors, G-Protein-Coupled; Thiazepines; Triazoles; Ustekinumab	2018
[Ursodeoxycholic acid combined with bezafibrate in the treatment of refractory primary biliary cholangitis: a meta-analysis]. Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2019, Apr-20, Volume: 27, Issue:4 Topics: Bezafibrate; Drug Therapy, Combination; Humans; Liver Cirrhosis, Biliary; Randomized Controlled Trials as Topic; Treatment Outcome; Ursodeoxycholic Acid	2019
Optimal drug regimens for primary biliary cirrhosis: a systematic review and network meta-analysis. Oncotarget, 2015, Sep-15, Volume: 6, Issue:27 Topics: Adrenal Cortex Hormones; Adult; Aged; Azathioprine; Bezafibrate; Bile Ducts; Colchicine; Cyclosporine; Drug Therapy, Combination; Female; Humans; Liver Cirrhosis, Biliary; Male; Methotrexate; Middle Aged; Penicillamine; Treatment Outcome; Ursodeoxycholic Acid	2015
Systematic review and meta-analysis: bezafibrate in patients with primary biliary cirrhosis. Drug design, development and therapy, 2015, Volume: 9 Topics: Bezafibrate; Biomarkers; Chi-Square Distribution; Drug Therapy, Combination; Humans; Liver; Liver Cirrhosis, Biliary; Odds Ratio; Risk Factors; Treatment Outcome; Ursodeoxycholic Acid	2015
Novel Therapies on Primary Biliary Cirrhosis. Clinics in liver disease, 2016, Volume: 20, Issue:1 Topics: Abatacept; Anti-Retroviral Agents; Antibodies, Monoclonal, Humanized; Bezafibrate; Chenodeoxycholic Acid; Cholagogues and Choleretics; Fenofibrate; Glucocorticoids; Humans; Hypolipidemic Agents; Immunologic Factors; Liver Cirrhosis, Biliary; Mesenchymal Stem Cell Transplantation; Receptors, Cytoplasmic and Nuclear; Rituximab; Ursodeoxycholic Acid; Ustekinumab	2016
Bezafibrate for primary biliary cirrhosis. The Cochrane database of systematic reviews, 2012, Jan-18, Volume: 1 Topics: Alanine Transaminase; Alkaline Phosphatase; Bezafibrate; Bilirubin; Drug Therapy, Combination; gamma-Glutamyltransferase; Humans; Hypolipidemic Agents; Immunoglobulin M; Liver Cirrhosis, Biliary; Randomized Controlled Trials as Topic; Ursodeoxycholic Acid	2012
[Possibilities in the treatment of primary biliary cirrhosis]. Orvosi hetilap, 2005, Jun-05, Volume: 146, Issue:23 Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Retroviral Agents; Bezafibrate; Eosinophilia; Humans; Hypolipidemic Agents; Immunologic Factors; Immunosuppressive Agents; Liver Cirrhosis, Biliary; Liver Transplantation; Sulindac; Ursodeoxycholic Acid	2005

Trials

9 trial(s) available for bezafibrate and Liver Cirrhosis, Biliary

Article	Year
Fibrates for Itch (FITCH) in Fibrosing Cholangiopathies: A Double-Blind, Randomized, Placebo-Controlled Trial. Gastroenterology, 2021, Volume: 160, Issue:3 Topics: Adult; Bezafibrate; Cholangitis, Sclerosing; Double-Blind Method; Female; Humans; Liver Cirrhosis, Biliary; Male; Middle Aged; Placebos; Pruritus; Quality of Life; Severity of Illness Index; Treatment Outcome; Visual Analog Scale	2021
Fibrates for the treatment of cholestatic itch (FITCH): study protocol for a randomized controlled trial. Trials, 2017, 05-23, Volume: 18, Issue:1 Topics: Antipruritics; Bezafibrate; Cholangitis, Sclerosing; Clinical Protocols; Double-Blind Method; Humans; Liver Cirrhosis, Biliary; Netherlands; Pruritus; Research Design; Spain; Time Factors; Treatment Outcome	2017
A Placebo-Controlled Trial of Bezafibrate in Primary Biliary Cholangitis. The New England journal of medicine, 2018, Jun-07, Volume: 378, Issue:23 Topics: Adult; Bezafibrate; Bile Acids and Salts; Cholangitis; Double-Blind Method; Female; Humans; Hypolipidemic Agents; Liver Cirrhosis, Biliary; Male; Middle Aged; Placebos; Treatment Failure; Ursodeoxycholic Acid	2018
A prospective randomized controlled study of long-term combination therapy using ursodeoxycholic acid and bezafibrate in patients with primary biliary cirrhosis and dyslipidemia. The American journal of gastroenterology, 2015, Volume: 110, Issue:3 Topics: Alkaline Phosphatase; Bezafibrate; Cholagogues and Choleretics; Creatinine; Dose-Response Relationship, Drug; Drug Monitoring; Drug Therapy, Combination; Dyslipidemias; Female; Humans; Hypolipidemic Agents; Liver Cirrhosis, Biliary; Male; Middle Aged; Myalgia; Prognosis; Renal Insufficiency; Survival Rate; Time; Treatment Outcome; Ursodeoxycholic Acid	2015
Therapeutic effect of bezafibrate against biliary damage: a study of phospholipid secretion via the PPARalpha-MDR3 pathway. International journal of clinical pharmacology and therapeutics, 2010, Volume: 48, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Alkaline Phosphatase; ATP Binding Cassette Transporter, Subfamily B; Bezafibrate; Cholestasis; Drainage; Fatty Liver; Female; gamma-Glutamyltransferase; Humans; Hypolipidemic Agents; Jaundice, Obstructive; Liver Cirrhosis, Biliary; Male; Middle Aged; Phospholipids; Polymerase Chain Reaction; PPAR alpha	2010
Anticholestatic effects of bezafibrate in patients with primary biliary cirrhosis treated with ursodeoxycholic acid. Hepatology (Baltimore, Md.), 2013, Volume: 57, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Bezafibrate; Carcinoma, Hepatocellular; Cell Line, Tumor; Cholagogues and Choleretics; Cytochrome P-450 CYP3A; Drug Therapy, Combination; Female; Humans; Lipids; Liver; Liver Cirrhosis, Biliary; Liver Neoplasms; Male; Middle Aged; PPAR alpha; Pregnane X Receptor; Receptors, Steroid; Treatment Failure; Treatment Outcome; Ursodeoxycholic Acid	2013
Bezafibrate treatment: a new medical approach for PBC patients? Journal of gastroenterology, 2003, Volume: 38, Issue:6 Topics: Alkaline Phosphatase; Bezafibrate; Bile Acids and Salts; Cholagogues and Choleretics; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Hypolipidemic Agents; Liver Cirrhosis, Biliary; Male; Middle Aged; Time Factors; Ursodeoxycholic Acid	2003
Bezafibrate may attenuate biliary damage associated with chronic liver diseases accompanied by high serum biliary enzyme levels. Journal of gastroenterology, 2006, Volume: 41, Issue:7 Topics: Aged; Alkaline Phosphatase; Bezafibrate; Biliary Tract; Chronic Disease; Female; gamma-Glutamyltransferase; Humans; Hypolipidemic Agents; Liver Cirrhosis, Biliary; Liver Diseases; Male; Middle Aged; Treatment Outcome	2006
Bezafibrate in the treatment of primary biliary cirrhosis: comparison with ursodeoxycholic acid. The American journal of gastroenterology, 2000, Volume: 95, Issue:10 Topics: Aged; Autoimmune Diseases; Bezafibrate; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Liver Cirrhosis, Biliary; Liver Function Tests; Male; Middle Aged; Ursodeoxycholic Acid	2000

Other Studies

42 other study(ies) available for bezafibrate and Liver Cirrhosis, Biliary

Article	Year
Bezafibrate therapy in primary biliary cholangitis refractory to ursodeoxycholic acid: a longitudinal study of paired liver biopsies at 5 years of follow up. Alimentary pharmacology & therapeutics, 2021, Volume: 54, Issue:9 Topics: Bezafibrate; Biopsy; Cholagogues and Choleretics; Drug Therapy, Combination; Follow-Up Studies; Humans; Liver Cirrhosis, Biliary; Longitudinal Studies; Ursodeoxycholic Acid	2021
Editorial: bezafibrate in the treatment of patients with primary biliary cholangitis-are we there yet? Authors' reply. Alimentary pharmacology & therapeutics, 2022, Volume: 55, Issue:2 Topics: Bezafibrate; Cholangitis; Humans; Liver Cirrhosis, Biliary; Ursodeoxycholic Acid	2022
Editorial: bezafibrate in the treatment of patients with primary biliary cholangitis-are we there yet? Alimentary pharmacology & therapeutics, 2022, Volume: 55, Issue:2 Topics: Bezafibrate; Cholangitis; Humans; Liver Cirrhosis, Biliary; Ursodeoxycholic Acid	2022
IgM response is a prognostic biomarker of primary biliary cholangitis treated with ursodeoxycholic acid and bezafibrate. Journal of gastroenterology and hepatology, 2020, Volume: 35, Issue:4 Topics: Bezafibrate; Biomarkers; Drug Therapy, Combination; Female; Humans; Immunoglobulin M; Liver Cirrhosis, Biliary; Male; Middle Aged; Prognosis; Retrospective Studies; Survival Rate; Time Factors; Treatment Outcome; Ursodeoxycholic Acid	2020
Switching vs. add-on strategy in PBC treatment: Lessons from UDCA and bezafibrate experience. Journal of hepatology, 2020, Volume: 72, Issue:6 Topics: Bezafibrate; Cholagogues and Choleretics; Humans; Liver Cirrhosis, Biliary; Ursodeoxycholic Acid	2020
Reply to: "Switching vs. add-on strategy in PBC treatment: Lessons from UDCA and bezafibrate experience". Journal of hepatology, 2020, Volume: 72, Issue:6 Topics: Bezafibrate; Cholagogues and Choleretics; Humans; Liver Cirrhosis, Biliary; Ursodeoxycholic Acid	2020
A validation study of the Ursodeoxycholic Acid Response Score in Japanese patients with primary biliary cholangitis. Liver international : official journal of the International Association for the Study of the Liver, 2020, Volume: 40, Issue:8 Topics: Aged; Alkaline Phosphatase; Bezafibrate; Cholagogues and Choleretics; Female; Humans; Japan; Liver Cirrhosis, Biliary; Male; Middle Aged; Ursodeoxycholic Acid	2020
Improved Markers of Cholestatic Liver Injury in Patients With Primary Biliary Cholangitis Treated With Obeticholic Acid and Bezafibrate. Hepatology (Baltimore, Md.), 2021, Volume: 73, Issue:6 Topics: Alkaline Phosphatase; Bezafibrate; Bilirubin; Chenodeoxycholic Acid; Cholestasis; Cholesterol; Dose-Response Relationship, Drug; Drug Interactions; Drug Monitoring; Female; Humans; Hypolipidemic Agents; Liver Cirrhosis, Biliary; Liver Function Tests; Male; Middle Aged; Pruritus; Treatment Outcome	2021
Association of bezafibrate with transplant-free survival in patients with primary biliary cholangitis. Journal of hepatology, 2021, Volume: 75, Issue:3 Topics: Adult; Bezafibrate; Cohort Studies; Female; Humans; Japan; Liver Cirrhosis, Biliary; Male; Middle Aged; Prognosis; Proportional Hazards Models; Retrospective Studies; Treatment Outcome	2021
Obeticholic Acid and Fibrates in Primary Biliary Cholangitis: Comparative Effects in a Multicentric Observational Study. The American journal of gastroenterology, 2021, 11-01, Volume: 116, Issue:11 Topics: Bezafibrate; Chenodeoxycholic Acid; Female; Fenofibrate; Humans; Liver Cirrhosis, Biliary; Male; Middle Aged; Retrospective Studies; Treatment Outcome	2021
Effects of Bezafibrate on Outcome and Pruritus in Primary Biliary Cholangitis With Suboptimal Ursodeoxycholic Acid Response. The American journal of gastroenterology, 2018, Volume: 113, Issue:1 Topics: Alkaline Phosphatase; Bezafibrate; Carcinoma, Hepatocellular; Cholagogues and Choleretics; Disease Progression; Drug Therapy, Combination; Elasticity Imaging Techniques; Female; Humans; Hypolipidemic Agents; Jaundice; Liver Cirrhosis, Biliary; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Prognosis; Pruritus; Ursodeoxycholic Acid; Visual Analog Scale	2018
Editorial: Itching to Know: Role of Fibrates in PBC. The American journal of gastroenterology, 2018, Volume: 113, Issue:1 Topics: Bezafibrate; Cholangitis; Fibric Acids; Humans; Liver Cirrhosis, Biliary; Pruritus; Ursodeoxycholic Acid	2018
Bezafibrate in Primary Biliary Cholangitis. The New England journal of medicine, 2018, Sep-06, Volume: 379, Issue:10 Topics: Bezafibrate; Cholangitis; Humans; Hypolipidemic Agents; Liver Cirrhosis, Biliary	2018
Bezafibrate in Primary Biliary Cholangitis. The New England journal of medicine, 2018, 09-06, Volume: 379, Issue:10 Topics: Bezafibrate; Cholangitis; Humans; Liver Cirrhosis, Biliary; Ursodeoxycholic Acid	2018
Antipruritic effect of bezafibrate and serum autotaxin measures in patients with primary biliary cholangitis. Gut, 2019, Volume: 68, Issue:10 Topics: Antipruritics; Bezafibrate; Cholangitis; Gastroenterology; Humans; Liver Cirrhosis, Biliary; United Kingdom	2019
In primary biliary cholangitis, adding bezafibrate to ursodeoxycholic acid increased complete biochemical response. Annals of internal medicine, 2018, 10-16, Volume: 169, Issue:8 Topics: Bezafibrate; Cholangitis; Humans; Liver Cirrhosis, Biliary; Ursodeoxycholic Acid	2018
[Bezafibrate for primary biliary cholangitis : Bezafibrate in combination with ursodeoxycholic acid in primary biliary cholangitis (BEZURSO) trial]. Der Internist, 2018, Volume: 59, Issue:12 Topics: Bezafibrate; Cholangitis; Humans; Liver Cirrhosis, Biliary; Ursodeoxycholic Acid	2018
Letter: reduction in projected mortality or need for liver transplantation associated with bezafibrate add-on in primary biliary cholangitis with incomplete UDCA response. Alimentary pharmacology & therapeutics, 2019, Volume: 49, Issue:2 Topics: Bezafibrate; Cholangitis; Fenofibrate; Humans; Liver Cirrhosis, Biliary; Liver Transplantation; Ursodeoxycholic Acid	2019
The Role of Bezafibrate, a Peroxisome Proliferator-Activated Receptor Alpha Agonist, in Patients With Primary Biliary Cholangitis. Hepatology (Baltimore, Md.), 2019, Volume: 69, Issue:6 Topics: Bezafibrate; Humans; Liver Cirrhosis, Biliary; PPAR alpha	2019
Additional fibrate treatment in UDCA-refractory PBC patients. Liver international : official journal of the International Association for the Study of the Liver, 2019, Volume: 39, Issue:9 Topics: Alkaline Phosphatase; Bezafibrate; Cholagogues and Choleretics; Drug Therapy, Combination; Female; Fenofibrate; Humans; Liver Cirrhosis, Biliary; Male; Middle Aged; Proportional Hazards Models; Retrospective Studies; Ursodeoxycholic Acid	2019
BAFF promotes regulatory T-cell apoptosis and blocks cytokine production by activating B cells in primary biliary cirrhosis. Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas, 2013, Volume: 46, Issue:5 Topics: Apoptosis; B-Cell Activating Factor; B-Lymphocytes; B-Lymphocytes, Regulatory; Bezafibrate; Cytokines; Enzyme-Linked Immunosorbent Assay; Female; Flow Cytometry; Humans; Liver Cirrhosis, Biliary; Lymphocyte Activation; Male; Middle Aged	2013
Bezafibrate normalizes alkaline phosphatase in primary biliary cirrhosis patients with incomplete response to ursodeoxycholic acid. Liver international : official journal of the International Association for the Study of the Liver, 2014, Volume: 34, Issue:2 Topics: Alkaline Phosphatase; Bezafibrate; Elasticity Imaging Techniques; Female; Humans; Liver Cirrhosis, Biliary; Middle Aged; Pilot Projects; Prospective Studies; Statistics, Nonparametric; Treatment Outcome; Ursodeoxycholic Acid	2014
Effectiveness of fenofibrate in comparison to bezafibrate for patients with asymptomatic primary biliary cirrhosis. Fukuoka igaku zasshi = Hukuoka acta medica, 2013, Volume: 104, Issue:10 Topics: Adult; Aged; Asymptomatic Diseases; Bezafibrate; Cardiovascular Diseases; Cholesterol, LDL; Cohort Studies; Drug Therapy, Combination; Dyslipidemias; Female; Fenofibrate; Humans; Liver Cirrhosis, Biliary; Male; Middle Aged; PPAR alpha; Prognosis; Renal Insufficiency; Retrospective Studies; Risk Factors; Uric Acid; Ursodeoxycholic Acid	2013
Overlap of IgG4-related sclerosing cholangitis and primary biliary cirrhosis. Internal medicine (Tokyo, Japan), 2014, Volume: 53, Issue:13 Topics: Bezafibrate; Cholagogues and Choleretics; Cholangitis, Sclerosing; Drug Therapy, Combination; Humans; Immunoglobulin G; Liver Cirrhosis, Biliary; Male; Middle Aged; Ursodeoxycholic Acid	2014
Biochemical responses to bezafibrate improve long-term outcome in asymptomatic patients with primary biliary cirrhosis refractory to UDCA. Journal of gastroenterology, 2015, Volume: 50, Issue:6 Topics: Adult; Aged; Alanine Transaminase; Bezafibrate; Databases, Factual; Drug Therapy, Combination; Female; Humans; Hypolipidemic Agents; Liver Cirrhosis, Biliary; Male; Middle Aged; Multivariate Analysis; Retrospective Studies; Treatment Outcome; Ursodeoxycholic Acid	2015
Combination Therapy of Ursodeoxycholic Acid and Bezafibrate in Patients With Primary Biliary Cirrhosis: The End of the Steroid Era in Autoimmune Liver Diseases? The American journal of gastroenterology, 2015, Volume: 110, Issue:7 Topics: Bezafibrate; Dyslipidemias; Female; Humans; Liver Cirrhosis, Biliary; Male; Myalgia; Renal Insufficiency; Ursodeoxycholic Acid	2015
Response to Licinio et al. The American journal of gastroenterology, 2015, Volume: 110, Issue:7 Topics: Bezafibrate; Dyslipidemias; Female; Humans; Liver Cirrhosis, Biliary; Male; Myalgia; Renal Insufficiency; Ursodeoxycholic Acid	2015
Identification of microRNA profiles associated with refractory primary biliary cirrhosis. Molecular medicine reports, 2016, Volume: 14, Issue:4 Topics: Adult; Aged; Anti-Inflammatory Agents; Bezafibrate; Cholagogues and Choleretics; Drug Resistance; Female; Gene Expression Regulation; Humans; Hypolipidemic Agents; Liver Cirrhosis, Biliary; Male; MicroRNAs; Middle Aged; Prednisolone; Transcriptome; Ursodeoxycholic Acid	2016
Comment on biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis. Hepatology (Baltimore, Md.), 2009, Volume: 49, Issue:1 Topics: Alkaline Phosphatase; Bezafibrate; Cholagogues and Choleretics; Drug Synergism; Fenofibrate; Humans; Immunoglobulin M; Liver Cirrhosis, Biliary; Prognosis; Ursodeoxycholic Acid	2009
Additive improvement induced by bezafibrate in patients with primary biliary cirrhosis showing refractory response to ursodeoxycholic acid. Journal of gastroenterology and hepatology, 2011, Volume: 26, Issue:9 Topics: Adult; Aged; Alkaline Phosphatase; Bezafibrate; Biomarkers; Drug Resistance; Drug Therapy, Combination; Female; Humans; Immunoglobulin M; Japan; Liver Cirrhosis, Biliary; Logistic Models; Male; Middle Aged; Prospective Studies; Time Factors; Treatment Failure; Ursodeoxycholic Acid	2011
Case of primary biliary cirrhosis-autoimmune hepatitis overlap which manifested after delivery. Internal medicine (Tokyo, Japan), 2011, Volume: 50, Issue:12 Topics: Adult; Bezafibrate; Cholagogues and Choleretics; Female; Hepatitis, Autoimmune; Humans; Liver Cirrhosis, Biliary; Postpartum Period; Pregnancy; Ursodeoxycholic Acid	2011
No more pilots, a phase III trial of fibrates in primary biliary cirrhosis is long overdue! Journal of gastroenterology and hepatology, 2011, Volume: 26, Issue:9 Topics: Bezafibrate; Female; Humans; Liver Cirrhosis, Biliary; Male; Ursodeoxycholic Acid	2011
Fibrates as adjuvant therapy for chronic cholestatic liver disease: its time has come. Hepatology (Baltimore, Md.), 2013, Volume: 57, Issue:5 Topics: Anticholesteremic Agents; Bezafibrate; Cholagogues and Choleretics; Female; Humans; Liver Cirrhosis, Biliary; Male; Ursodeoxycholic Acid	2013
[Management of PBC cases failing to respond to UDCA]. Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology, 2013, Volume: 110, Issue:1 Topics: Bezafibrate; Humans; Liver Cirrhosis, Biliary; Ursodeoxycholic Acid	2013
New weapon for primary biliary cirrhosis from Japan. Journal of gastroenterology, 2003, Volume: 38, Issue:6 Topics: Bezafibrate; Bile Acids and Salts; Drug Therapy, Combination; Humans; Hypolipidemic Agents; Liver Cirrhosis, Biliary; Ursodeoxycholic Acid	2003
Therapeutic efficacy of decreased nitrite production by bezafibrate in patients with primary biliary cirrhosis. Journal of gastroenterology, 2005, Volume: 40, Issue:2 Topics: Adult; Bezafibrate; Female; Humans; Hypolipidemic Agents; Liver Cirrhosis, Biliary; Liver Function Tests; Middle Aged; Nitrites	2005
Long-term fibrate treatment for PBC. Journal of gastroenterology, 2005, Volume: 40, Issue:5 Topics: Administration, Oral; Bezafibrate; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Hypolipidemic Agents; Liver Cirrhosis, Biliary; Long-Term Care; Sampling Studies; Treatment Outcome	2005
Long-term effect of bezafibrate on parameters of hepatic fibrosis in primary biliary cirrhosis. Journal of gastroenterology, 2006, Volume: 41, Issue:5 Topics: Administration, Oral; Adult; Aged; Bezafibrate; Female; Humans; Liver Cirrhosis; Liver Cirrhosis, Biliary; Male; Middle Aged	2006
Combination therapy of bezafibrate and ursodeoxycholic acid in primary biliary cirrhosis: a preliminary study. The American journal of gastroenterology, 2000, Volume: 95, Issue:1 Topics: Aged; Alkaline Phosphatase; Bezafibrate; Cholagogues and Choleretics; Drug Therapy, Combination; gamma-Glutamyltransferase; Humans; Hypolipidemic Agents; Immunoglobulin M; Liver Cirrhosis, Biliary; Middle Aged; Pilot Projects; Ursodeoxycholic Acid	2000
Effect of bezafibrate in primary biliary cirrhosis: a pilot study. Liver, 2001, Volume: 21, Issue:3 Topics: Adult; Aged; Alanine Transaminase; Alkaline Phosphatase; Bezafibrate; Female; gamma-Glutamyltransferase; Humans; Hypolipidemic Agents; Immunoglobulin M; Liver Cirrhosis, Biliary; Male; Middle Aged; Pilot Projects; Time Factors; Treatment Outcome; Ursodeoxycholic Acid	2001
Investigation into the efficacy of bezafibrate against primary biliary cirrhosis, with histological references from cases receiving long term monotherapy. The American journal of gastroenterology, 2002, Volume: 97, Issue:1 Topics: Aged; Bezafibrate; Biopsy, Needle; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Hypolipidemic Agents; Liver Cirrhosis, Biliary; Liver Function Tests; Middle Aged	2002
Is bezafibrate histologically effective for primary biliary cirrhosis? The American journal of gastroenterology, 2002, Volume: 97, Issue:4 Topics: Aged; Aged, 80 and over; Bezafibrate; Female; Humans; Hypolipidemic Agents; Liver Cirrhosis, Biliary; Male; Middle Aged	2002